Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 24;14(11):2580. doi: 10.3390/cancers14112580

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

MUC1-high TNBC tumors associate with type I IFN and inflammatory signaling pathways. (A,B) Enrichment plots for the HALLMARK INTERFERON ALPHA RESPONSE pathway, comparing MUC1-high to MUC1-low TNBC tumors in the TCGA-BRCA (A) and METABRIC (B) cohorts. (C) Scatter plots showing correlations of MUC1 with STAT2 and IRF9 in TNBCs from the METABRIC cohort. (D) Scatter plot of the correlation between MUC1 and IRF9 in single TNBC cells as analyzed from the GSE118389 scRNA-seq dataset. (E) Scatter plots showing correlations of MUC1 with IFIT2, IFIT3, OAS2 and OASL in TNBCs from the TCGA-BRCA and METABRIC TNBC cohorts. (F,G) Enrichment plots for the HALLMARK INFLAMMATORY RESPONSE pathway, comparing MUC1-high to MUC1-low TNBC tumors in the TCGA-BRCA (F) and METABRIC (G) cohorts.